258 related articles for article (PubMed ID: 24354805)
1. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors.
Koumangoye RB; Nangami GN; Thompson PD; Agboto VK; Ochieng J; Sakwe AM
Mol Cancer; 2013 Dec; 12(1):167. PubMed ID: 24354805
[TBL] [Abstract][Full Text] [Related]
2. Annexin A6 improves anti-migratory and anti-invasive properties of tyrosine kinase inhibitors in EGFR overexpressing human squamous epithelial cells.
Hoque M; Elmaghrabi YA; Köse M; Beevi SS; Jose J; Meneses-Salas E; Blanco-Muñoz P; Conway JRW; Swarbrick A; Timpson P; Tebar F; Enrich C; Rentero C; Grewal T
FEBS J; 2020 Jul; 287(14):2961-2978. PubMed ID: 31869496
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors.
Widatalla SE; Korolkova OY; Whalen DS; Goodwin JS; Williams KP; Ochieng J; Sakwe AM
Carcinogenesis; 2019 Aug; 40(8):998-1009. PubMed ID: 30590459
[TBL] [Abstract][Full Text] [Related]
4. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Li T; Tao Z; Zhu Y; Liu X; Wang L; Du Y; Cao J; Wang B; Zhang J; Hu X
Cell Death Dis; 2021 Jul; 12(7):684. PubMed ID: 34238922
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists.
Williams SD; Smith TM; Stewart LV; Sakwe AM
Cells; 2022 Sep; 11(19):. PubMed ID: 36230969
[TBL] [Abstract][Full Text] [Related]
6. Annexin A6 contributes to the invasiveness of breast carcinoma cells by influencing the organization and localization of functional focal adhesions.
Sakwe AM; Koumangoye R; Guillory B; Ochieng J
Exp Cell Res; 2011 Apr; 317(6):823-37. PubMed ID: 21185831
[TBL] [Abstract][Full Text] [Related]
7. Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies.
Korolkova OY; Widatalla SE; Williams SD; Whalen DS; Beasley HK; Ochieng J; Grewal T; Sakwe AM
Cells; 2020 Aug; 9(8):. PubMed ID: 32784650
[TBL] [Abstract][Full Text] [Related]
8. SUMOylation of AnxA6 facilitates EGFR-PKCα complex formation to suppress epithelial cancer growth.
Sheng Z; Cao X; Deng YN; Zhao X; Liang S
Cell Commun Signal; 2023 Aug; 21(1):189. PubMed ID: 37528485
[TBL] [Abstract][Full Text] [Related]
9. Annexin A6 is a scaffold for PKCα to promote EGFR inactivation.
Koese M; Rentero C; Kota BP; Hoque M; Cairns R; Wood P; Vilà de Muga S; Reverter M; Alvarez-Guaita A; Monastyrskaya K; Hughes WE; Swarbrick A; Tebar F; Daly RJ; Enrich C; Grewal T
Oncogene; 2013 Jun; 32(23):2858-72. PubMed ID: 22797061
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
11. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets.
Korolkova OY; Widatalla SE; Whalen DS; Nangami GN; Abimbola A; Williams SD; Beasley HK; Reisenbichler E; Washington MK; Ochieng J; Mayer IA; Lehmann BD; Sakwe AM
PLoS One; 2020; 15(4):e0231711. PubMed ID: 32298357
[TBL] [Abstract][Full Text] [Related]
12. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.
Lee SY; Meier R; Furuta S; Lenburg ME; Kenny PA; Xu R; Bissell MJ
J Clin Invest; 2012 Sep; 122(9):3211-20. PubMed ID: 22886303
[TBL] [Abstract][Full Text] [Related]
13. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Irwin ME; Mueller KL; Bohin N; Ge Y; Boerner JL
J Cell Physiol; 2011 Sep; 226(9):2316-28. PubMed ID: 21660955
[TBL] [Abstract][Full Text] [Related]
14. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
Zhang L; Ngo JA; Wetzel MD; Marchetti D
Neoplasia; 2015 Jan; 17(1):101-13. PubMed ID: 25622903
[TBL] [Abstract][Full Text] [Related]
15. HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
Gschwantler-Kaulich D; Grunt TW; Muhr D; Wagner R; Kölbl H; Singer CF
PLoS One; 2016; 11(1):e0146311. PubMed ID: 26735495
[TBL] [Abstract][Full Text] [Related]
16. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
[TBL] [Abstract][Full Text] [Related]
17. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.
Borrero-García LD; Del Mar Maldonado M; Medina-Velázquez J; Troche-Torres AL; Velazquez L; Grafals-Ruiz N; Dharmawardhane S
BMC Cancer; 2021 Jun; 21(1):652. PubMed ID: 34074257
[TBL] [Abstract][Full Text] [Related]
18. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility.
Whalen DS; Widatalla SE; Korolkova OY; Nangami GS; Beasley HK; Williams SD; Virgous C; Lehmann BD; Ochieng J; Sakwe AM
Oncotarget; 2019 Jan; 10(2):133-151. PubMed ID: 30719209
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
